Monthly Prescribing Reference

Breo Ellipta

Fluticasone furoate, vilanterol 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Increased risk of asthma-related events (death, hospitalizations, intubations) with LABA monotherapy (without ICS).
The Times Leader

FDA panel backs inhaler drug for lung disease

(AP) A panel of respiratory experts has voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease. A majority of Food and Drug ...
Healthline

Trelegy Ellipta Interactions: Alcohol, Medications, and Others

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription inhaler used to treat asthma or COPD in adults. This drug can interact with certain ...
Washington Examiner

FDA approves once-a-day inhaler from Glaxo

WASHINGTON (AP) — The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta ...
Business Wire

Global BREO Ellipta Drugs Market to Witness Rapid Growth by 2031, Fueled by Growing Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs market is driven ...
Monthly Prescribing Reference

Breo Ellipta

Fluticasone furoate, vilanterol 50/25mcg, 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. The ...